Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry P Erba

Showing results (51-60 of 123) with videos related to

Pageof 13
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2014
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapyMegan Othus, Frederick R Appelbaum, Stephen H Petersdorf, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemiaLaura W Dillon, Jake Higgins, Hassan Nasif, et al.
The Journal of Molecular Diagnostics : JMD|July 30, 2023
Genomic Data Heterogeneity across Molecular Diagnostic Laboratories: A Real-World Connect Myeloid Disease Registry Perspective on Variabilities in Genomic Assay Methodology and ReportingJay L Patel, Harry P Erba, Michael R Savona, et al.
British Journal of Haematology|March 4, 2015
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 studyRonan T Swords, Harry P Erba, Daniel J DeAngelo, et al.
Haematologica|August 3, 2023
Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemiaLaura W Dillon, Jake Higgins, Hassan Nasif, et al.
Blood Neoplasia|September 11, 2025
V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AMLVinod A Pullarkat, Mark Levis, James McCloskey, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 29, 2009
NCCN task force report: molecular markers in leukemias and lymphomasJerald P Radich, Andrew D Zelenetz, Wing C Chan, et al.
Blood|April 18, 2013
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemiaStephen H Petersdorf, Kenneth J Kopecky, Marilyn Slovak, et al.
Leukemia & Lymphoma|April 19, 2018
Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey<sup>.</sup>Maximilian Stahl, Alexander Pine, Jeanne E Hendrickson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factorsHagop M Kantarjian, Harry P Erba, David Claxton, et al.
Pageof 13

Showing results (51-60 of 123) with videos related to

Sort By:
Pageof 13
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2014
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapyMegan Othus, Frederick R Appelbaum, Stephen H Petersdorf, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemiaLaura W Dillon, Jake Higgins, Hassan Nasif, et al.
The Journal of Molecular Diagnostics : JMD|July 30, 2023
Genomic Data Heterogeneity across Molecular Diagnostic Laboratories: A Real-World Connect Myeloid Disease Registry Perspective on Variabilities in Genomic Assay Methodology and ReportingJay L Patel, Harry P Erba, Michael R Savona, et al.
British Journal of Haematology|March 4, 2015
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 studyRonan T Swords, Harry P Erba, Daniel J DeAngelo, et al.
Haematologica|August 3, 2023
Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemiaLaura W Dillon, Jake Higgins, Hassan Nasif, et al.
Blood Neoplasia|September 11, 2025
V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AMLVinod A Pullarkat, Mark Levis, James McCloskey, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 29, 2009
NCCN task force report: molecular markers in leukemias and lymphomasJerald P Radich, Andrew D Zelenetz, Wing C Chan, et al.
Blood|April 18, 2013
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemiaStephen H Petersdorf, Kenneth J Kopecky, Marilyn Slovak, et al.
Leukemia & Lymphoma|April 19, 2018
Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey<sup>.</sup>Maximilian Stahl, Alexander Pine, Jeanne E Hendrickson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factorsHagop M Kantarjian, Harry P Erba, David Claxton, et al.
Pageof 13